Tech Company Financing Transactions

Shape Therapeutics Funding Round

Shape Therapeutics, based in Seattle, scored $35.5 million in funding from New Enterprise Associates and CureDuchenne Ventures.

Transaction Overview

Company Name
Shape Therapeutics
Announced On
11/6/2019
Transaction Type
Venture Equity
Amount
$35,500,000
Round
Series A
Investors

New Enterprise Associates (Lead Investor) (Ed Mathers)

CureDuchenne Ventures (Debra Miller)

Proceeds Purpose
The new capital will enable the company to extend its growing portfolio of intellectual property, recruit and hire top scientific talent and advance its groundbreaking RNA and protein targeting platforms focused on curing human diseases.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
219 Terry Ave. N 100
Seattle, WA 98109
USA
Phone
Undisclosed
Website
www.shapetx.com
Email Address
[email protected]
Overview
Shape Therapeutics' next-generation gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases.
Profile
Shape Therapeutics LinkedIn Company Profile
Social Media
Shape Therapeutics Company Twitter Account
Company News
Shape Therapeutics News
Facebook
Shape Therapeutics on Facebook
YouTube
Shape Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Francois Vigneault
  Francois Vigneault LinkedIn Profile  Francois Vigneault Twitter Account  Francois Vigneault News  Francois Vigneault on Facebook
Chief Financial Officer
John Suliman
  John Suliman LinkedIn Profile  John Suliman Twitter Account  John Suliman News  John Suliman on Facebook
Chief Operating Officer
Gary Fortin
  Gary Fortin LinkedIn Profile  Gary Fortin Twitter Account  Gary Fortin News  Gary Fortin on Facebook
Executive Vice President
Rafael Ponce
  Rafael Ponce LinkedIn Profile  Rafael Ponce Twitter Account  Rafael Ponce News  Rafael Ponce on Facebook
Vice President
Joseph Biedenkapp
  Joseph Biedenkapp LinkedIn Profile  Joseph Biedenkapp Twitter Account  Joseph Biedenkapp News  Joseph Biedenkapp on Facebook
Vice President
Ron Hause
  Ron Hause LinkedIn Profile  Ron Hause Twitter Account  Ron Hause News  Ron Hause on Facebook
VP - Bus. Development
Patrick Bigot
  Patrick Bigot LinkedIn Profile  Patrick Bigot Twitter Account  Patrick Bigot News  Patrick Bigot on Facebook
VP - Finance
William Krause
  William Krause LinkedIn Profile  William Krause Twitter Account  William Krause News  William Krause on Facebook
VP - General Counsel
Lisa Ash
  Lisa Ash LinkedIn Profile  Lisa Ash Twitter Account  Lisa Ash News  Lisa Ash on Facebook
VP - Operations
Katherine Connor
  Katherine Connor LinkedIn Profile  Katherine Connor Twitter Account  Katherine Connor News  Katherine Connor on Facebook
VP - R & D
David Huss
  David Huss LinkedIn Profile  David Huss Twitter Account  David Huss News  David Huss on Facebook

 

 

Browse more venture capital transactions:

Prev: 11/6/2019: Imbed Biosciences venture capital transaction
Next: 11/6/2019: HomeLight venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.